Identification and clinical application for the role of NKT cells in patients with chronic hepatitis and hepatocellualr carcinoma infected hepatitis virus
Identification and clinical application for the role of NKT cells in patients with chronic hepatitis and hepatocellualr carcinoma infected hepatitis virus
批准号:
15390236
负责人:
KAKUMU Shinichi
金额:
$9.09万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2005
中文摘要
自然杀伤T(NKT)细胞具有经典T细胞和NK细胞的特征。NKT细胞是一种异质性细胞,识别与CD 1d分子相关的糖脂。我们研究了Th 1/Th 2细胞因子的产生以及循环NKT细胞的频率和表型在慢性肝炎(CH)和肝细胞癌(HCC)感染丙型肝炎病毒(HCV)的患者。分别在干扰素/利巴韦林和射频消融治疗CH和HCC前和治疗2周后采集外周血单个核细胞(PBMC)。用α半乳糖神经酰胺(α GalCer)和IL-2培养PBMC。用流式细胞术分析NKT细胞的频率和细胞因子产生。慢性丙型肝炎患者外周血中Vα 24+ CD 3 + T细胞IFN-γ的分泌无明显差异,但治疗后增加,而IL-4的分泌减少。然而,我们没有调整其功能的策略, ...更多信息 因此,我们希望通过激活V α 24+ NKT细胞来诱导成熟DC。我们培养的外周血CD 14+细胞的存在下,GMCSF和IL-4。同时用α GalCer + IL-2培养CD 3 + T细胞。培养5天后,将其与GMCSF、α GalCer和IL-2混合并再培养2天。细胞毒性T淋巴细胞(CTL)被认为是清除包括B型肝炎病毒(HBV)在内的急性感染中的病毒的主要效应物。持续性HBV感染的特征在于缺乏或弱的针对HBV的CTL应答,这被认为反映了对HBV抗原的耐受性。我们发现,α GalCer(小鼠V α 14+ NKT细胞的配体)强烈增强HBsAg对HBV特异性CTL的诱导和增殖。在被认为对HBV编码抗原耐受的HBsAg转基因小鼠中,单独给予HBsAg或α GalCer不能诱导HBsAg特异性CTL,但给予两种化合物可诱导CTL。使用针对细胞因子和CD 4 O配体的抗体的阻断实验表明,IL-2通过NKT活化介导α GalCer引起的CTL诱导的增强。少
英文摘要
Natural killer T (NKT) cells share features of both classical T cells and NK cells. NKT cells are heterogenous populations, and recognize glycolipids associated with CD1d molecule. We investigated Th1/Th2 cytokine production as well as frequency and phenotype of circulating NKT cells in patients with chronic hepatitis (CH) and hepatocellular carcinoma (HCC) infected with hepatitis C virus (HCV). Peripheral blood mononuclear cells (PBMC) were obtained befor and 2 weeks later IFN/ribavirin and radiofrequency ablation therapy for CH and HCC, respectively. PBMC were cultured with α galactosylceramide (α GalCer) and IL-2. Frequency and cytokine production of NKT cells were analyzed with flow cytometry. IFN-γ production of Vα 24+CD3+ T cells did not differ among groups, but became greater after treatment in contrast to lowered IL-4 production.The function of dendritic cells (DCs) appears to be decreased in patients with chronic hepatitis C. However, we have no strategy to modulate its functi … More on. Thus we wanted to induce maturated DC by activating V α 24+ NKT cells. We cultured peripheral blood CD14+ cells in the presence of GMCSF and IL-4. Simultaneously CD3+ T cells were cultured with α GalCer + IL-2. After 5-day culture, they are mixed and cultured with GMCSF, α GalCer and IL-2 for further 2 days. This method induced matured, functional DC.Cytotoxic T lymphocyes (CTLs) are thought to be major effectors for clearing viruses in acute infections including hepatitis B virus (HBV). Persistent HBV infection is characterized by a lack of or a weak CTL response to HBV, which is thought to reflect tolerance to HBV antigens. We found that α GalCer, a ligand for V α 14+ NKT cells in mice, strongly enhanced the induction and proliferation of HBV-specific CTLs by HBsAg. In HbsAg transgenic mice, which are thought to be tolerant to HBV-encoded antigens, administration of HbsAg or α GalCer alone failed to HbsAg-specific CTLs, but they were induced by administration of both compounds. A blocking experiment using antibodies to cytokines and CD4O ligand showed that IL-2 mediates the enhancement of CTL induction caused by α GalCer through NKT activation. Less
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
The efficacy and safety of thymosin α1 in Japanese patients with chronic hepatitis B ; results of a randomized clinical trial.
胸腺肽α1对日本慢性乙型肝炎患者的疗效和安全性;一项随机临床试验的结果。
DOI:
--
发表时间:
2005
期刊:
J Viral Hepatitis 12
影响因子:
--
作者:
[Iino S, Toyota J, Kumada H, et al.]
通讯作者:
et al.
Kasahara S, et al.: "Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes"J Virol. 77. 2469-2477 (2003)
Kasahara S 等人:“缺乏肿瘤坏死因子 α 会导致乙型肝炎病毒特异性细胞毒性 T 淋巴细胞增殖受损”J Virol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Continued ribavirin monotherapy following interferon-ribavirin combination therapy is not effective for chronic hepatitis C.
干扰素-利巴韦林联合治疗后继续利巴韦林单药治疗对慢性丙型肝炎无效。
DOI:
--
发表时间:
2006
期刊:
Hepatol Res 32
影响因子:
--
作者:
[Dohmen K, Mizuta T, Ishibashi H, et al., Kakumu S.]
通讯作者:
Kakumu S.
Changes in natural killer T cell subsets during therapy in type C hepatitis and hepatocellular crcinoma.
丙型肝炎和肝细胞癌治疗期间自然杀伤 T 细胞亚群的变化。
DOI:
--
发表时间:
2005
期刊:
Hepatol Res 32
影响因子:
--
作者:
[Okumura A, Ishikawa T, Maeno T, et al.]
通讯作者:
et al.
Arao M, et al.: "Prevalence of diabetes among Japanese patients infected chronically with hepatitis C virus"J Gastroenterol. 38. 355-360 (2003)
Arao M 等人:“慢性感染丙型肝炎病毒的日本患者中糖尿病的患病率”J Gastroenterol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 9 条
To clarify the mechanism of chronicity and to explore therapeutic approach for viral hepatitis
-
批准号:12670529
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:2000
-
负责人:KAKUMU Shinichi
-
依托单位:
Pathologicl significance and its inhibition of apoptosis on the development and its progression of liver injury.
-
批准号:10470142
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$8.45万
-
财政年份:1998
-
负责人:KAKUMU Shinichi
-
依托单位:
IMMUNO-PATHOGENESIS AND-THERAPY OF VIRAL HEPATITIS
-
批准号:09044341
-
项目类别:Grant-in-Aid for international Scientific Research
-
资助金额:$2.24万
-
财政年份:1997
-
负责人:KAKUMU Shinichi
-
依托单位:
Cellular immune response against HBV nucleocapsid antigen
-
批准号:07457593
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$0.83万
-
财政年份:1995
-
负责人:KAKUMU Shinichi
-
依托单位:
Cellular immune response to core region protein of hepatitis C virus in patients with chronic hepatitis C
-
批准号:05454245
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$3.58万
-
财政年份:1993
-
负责人:KAKUMU Shinichi
-
依托单位:
Analysis of immunological mechanisms for antibody production to hepatitis B surface antigen.
-
批准号:60570317
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.15万
-
财政年份:1985
-
负责人:KAKUMU Shinichi
-
依托单位:
海外基金